Basch, E., Deal, A.M., Dueck, A.C., Scher, H.I., Kris, M.G., Hudis, C. and Schrag, D. (2017) Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA, 318, 197-198.
https://doi.org/10.1001/jama.2017.7156

has been cited by the following article:

• TITLE: Quality of Life in Ovarian-Cancer Patients Receiving Chemotherapy

  AUTHORS: Tohmina Akhter, Shahana Pervin, Annekathryn Goodman

  KEYWORDS: Quality of Life, EORTC QLQ C30, EORTC QOL OV-28, Ovarian Cancer, Chemotherapy, Bangladesh

  JOURNAL NAME: Journal of Cancer Therapy, Vol.11 No.11, November 19, 2020

  ABSTRACT: Background: Ovarian cancer accounts for 4% of cancers occurring in women and ranks first in gynecological cancer mortality. Maintaining and improving quality of life is an important goal of cancer treatment. The toxicities of cancer treatment particularly chemotherapy can impact an individual’s wellbeing. Objective: Assessment of quality of life among ovarian cancer patients receiving chemotherapy. Method: A descriptive study was conducted among 202 patients with ovarian cancer treated at the National Institute of Cancer Research and Hospital in Bangladesh. Ethical approval was received from the ethics committee of NICRH. Data was collected using the EORTC QLQC30 questionnaire and the ovarian cancer specific EORTC QOL OV-28 module. Functional, symptomatic and global variables were scored and analyzed by SPSS. Multiple linear regressions determined the effects of predictor variables and correlation of the global health status with other variables. Results: 48.6% of patients were ages 41 to 50 years. The mean score of global health status was 55.77. Deteriorating emotional function, distressing physical and psychological symptoms, sexual dysfunction and financial difficulties adversely affect the quality of life. Their correlation with global health status was strongly significant (P value -0.604; p -0.442; p -0.339; p -0.377; p -0.369; p -0.262; p Conclusion: The overall quality of life among the ovarian cancer patients receiving chemotherapy is low. Increasing knowledge in this area will help clinicians to optimize patient management. Interventions should focus on both physical and psychological and sexual health issues that adversely affect the quality of life.